Moteur de recherche d’entreprises européennes
Financement de l’UE (6 260 050 €) : DÉCISION SUR LES THÉRAPIES COMBINATOIRES OPTIMALES DANS LES IMID À L’AIDE D’APPROCHES SYSTÉMIQUES Hor 01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
DÉCISION SUR LES THÉRAPIES COMBINATOIRES OPTIMALES DANS LES IMID À L’AIDE D’APPROCHES SYSTÉMIQUES
Immune-Mediated Inflammatory Diseases (IMIDs) are a group of common autoimmune diseases that include clinically heterogeneous disorders such as rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and systemic lupus erythematosus. Despite their clinical heterogeneity, IMIDs share a significant number of features at the molecular and cellular levels. Recently developed therapies targeting common key molecules of the immune system like anti-TNF agents, have collectively resulted in a significant improvement in the management of IMIDs. Still, the complete control of the chronic inflammatory process is rarely attained, and too many patients experience a poor response, if at all. This inefficacy has become a major economic burden and severely impacts on the wellbeing of many European citizens. The DocTIS projects aims to profoundly change this trend by identifying highly effective combinatorial therapies as well as the group of patients where this response will be optimal. Using the standardized samples from one of the world’s largest biobanks specialized in IMIDs, new molecular data will be generated using advanced high-throughput technologies including single cell RNA-seq. Systems biology methods will be applied to this unique clinical and molecular data to model the response to targeted therapies and predict what drug combinations will act synergistically and on which types of patients. After validation in a preclinical stage, the optimal combinatorial therapy will be tested in a group of patients with a positive biomarker profile. Using a basket trial, a new type of clinical trial design that incorporates molecular marker information, the DocTIS project will provide proof of concept of the utility of combinatorial therapy and personalized medicine for the effective control of disease activity in IMIDs.
| Cardiff University | 936 106 € |
| Charite - Universitaetsmedizin Berlin | 61 250 € |
| Consorcio para La Explotacion del Centro Nacional de Analisis Genomico | 173 195 € |
| Fundacio Centre de Regulacio Genomica | 861 055 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 820 166 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 1 188 279 € |
| Hudsonalpha Institute FOR Biotechnology | 344 193 € |
| Imidomics Inc. | 683 201 € |
| Karolinska Institutet | 356 273 € |
| Linkopings Universitet | 329 725 € |
| Universita Degli Studi Di Verona | 151 250 € |
| Zabala Innovation Consulting SA | 355 356 € |
https://cordis.europa.eu/project/id/848028
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.